Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage (CRYSTALLBrain)
Primary Purpose
Subarachnoid Hemorrhage, Critical Illness, Infusion Fluid
Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
0.9% Sodium-chloride
Ringer's Lactate
Sponsored by
About this trial
This is an interventional other trial for Subarachnoid Hemorrhage
Eligibility Criteria
Inclusion Criteria:
All adult patients suffering from non-traumatic subarachnoid haemorrhage.
Exclusion Criteria:
- Patients with major intra-cranial trauma
- Diagnosis of an AV-malformation as the source of subarachnoid hemorrhage on the primary CT/MRI or angiography
- More than 24 hours after diagnosis of subarachnoid haemorrhage as diagnosed by cerebral imaging (CT scan or MRI)
- Patients with clear limitation to therapy at hospital admission (eg ICU admission for evaluation of organ donation)
- Declining of informed consent
Sites / Locations
- Department of Intensive Care, Bern University Hospital and University of Bern, Bern, SwitzerlandRecruiting
- Department of Intensive Care MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
high sodium infusion fluid
low sodium infusion fluid
Arm Description
Patients will exclusively receive 0.9% saline (sodium content 154mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
Patients will exclusively receive lactated Ringer's (sodium content 130mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
Outcomes
Primary Outcome Measures
Number of patients with clinically relevant vasospasms
Defined as new neurologic deficit requiring immediate intervention
Secondary Outcome Measures
Number of ICU deaths
Death on the ICU
Number of In-hospital deaths
Death during hospital stay
Number of severe vasospasms requiring endovascular treatment
Number of severe vasospasms requiring endovascular treatment
Number of patients needing decompressive hemicraniectomy
Operative intervention needed for high intracranial pressure
Difference in modified RankingScale
Scale ranges from 0-5 (0 = no symptoms; 5= severe disability)
Difference in Glasgow Outcome Scale
Scale ranges from 1-8 (1 is dead 7 good recovery)
Difference in mini Montreal Cognitive Assessment
Max score depends on age and education (the higher the score the better the cognition)
Difference in Long-term mortality
Death at 90 and 180 day
Length of stay
Length of hospital stay
Full Information
NCT ID
NCT04043598
First Posted
July 31, 2019
Last Updated
November 15, 2022
Sponsor
Insel Gruppe AG, University Hospital Bern
1. Study Identification
Unique Protocol Identification Number
NCT04043598
Brief Title
Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage
Acronym
CRYSTALLBrain
Official Title
Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage - a Multi-center Randomized Double-blind Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 24, 2022 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
March 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Patients with subarachnoid hemorrhage are prone to suffer from dysnatriemia. Evidence shows that hyponatriemia is associated with increased incidence of vasospasm, brain swelling and mortality in these patients. Patients with subarachnoid hemorrhage often require large amounts of iv fluids in order to maintain euvolemia and support cardiocirculatory function. Prior evidence shows that the type of infusion fluid significantly influences blood sodium content. Hence, this study evaluated whether the sodium content of the infusion solution impacts mortality and morbidity in patients with subarachnoid hemorrhage.
Detailed Description
Background: Despite ongoing advances in critical care mortality and morbidity of patients with subarachnoid hemorrhage remains high. Secondary brain injuries related to cerebral vasospasm and consecutive ischemic brain injury and intracerebral edema are the main contributors to mortality and morbidity in these patients. Evidence points towards low serum sodium levels being one of the significant risk factors for of secondary brain injury in this population. Previous studies show that fluid resuscitation with normal saline results in higher serum sodium levels and higher serum osmolality when compared to balanced infusates in patients with subarachnoid hemorrhage.
Aim: The primary objective of this study is to evaluate whether the use of a sodium-rich infusion (normal saline) results in better clinical outcome when compared to a sodium-depleted infusion (lactated Ringer's) in patients with subarachnoid hemorrhage. The primary endpoint will be the occurrence of clinically relevant vasospasm requiring immediate treatment. In addition, the investigators will assess other relevant complications such as long and short-term mortality, significant brain edema requiring conservative therapy or/and operative hemicraniectomy, as well as further patient-relevant outcomes such as days on organ support, postoperative infections, length of stay and long-term disability/mortality.
Study intervention: All patients admitted to a participating hospital with the diagnosis of intracerebral bleeding will be screened and if eligible, randomized to one of the study arms. Individual patient's consent will be sought. Thereafter, patients will receive only the allocated study fluid for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge. Neurological evaluation will be performed hourly for the initial phase and thereafter two hourly. Serum sodium, osmolality, fluid, water and electrolyte balance as well as acid-base homeostasis will be evaluated daily. Further, specific assessment of renal, cardiac and immune function takes place at 5 pre-specified time-points (day 1,3,7,10 and at ICU/IMC discharge).
After ICU/IMC discharge patients will be followed for evaluation of secondary endpoints. Long-term disability will be assessed by telephone interview based on the modified the Rankin-Scale and the Glasgow Outcome Scale Extended.
Sample Size: Sample size calculation was based upon the investigators' ICU's registry data. In 2017, 44.38% patients with subarachnoid hemorrhage reached the predefined endpoint of clinically relevant vasospasm requiring immediate intervention. A clinically relevant effect size was determined to be an improvement in outcome of 15%. Based on these results a patient number of n = 160 for each group was determined under estimation of a 15% drop out rate.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Subarachnoid Hemorrhage, Critical Illness, Infusion Fluid, Sodium Disorder
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Multi-center investigator-initiated randomized-controlled double blind clinical trial comparing to already established treatment protocols.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
double-blind randomized
Allocation
Randomized
Enrollment
320 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
high sodium infusion fluid
Arm Type
Active Comparator
Arm Description
Patients will exclusively receive 0.9% saline (sodium content 154mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
Arm Title
low sodium infusion fluid
Arm Type
Active Comparator
Arm Description
Patients will exclusively receive lactated Ringer's (sodium content 130mmol/l) for fluid maintenance and resuscitation from study inclusion until ICU/intermediate care (IMC) discharge.
Intervention Type
Drug
Intervention Name(s)
0.9% Sodium-chloride
Intervention Description
We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
Intervention Type
Drug
Intervention Name(s)
Ringer's Lactate
Intervention Description
We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
Primary Outcome Measure Information:
Title
Number of patients with clinically relevant vasospasms
Description
Defined as new neurologic deficit requiring immediate intervention
Time Frame
From ICU admission until discharge (usually within the first 21 days)
Secondary Outcome Measure Information:
Title
Number of ICU deaths
Description
Death on the ICU
Time Frame
From ICU admission until discharge (usually within the first 21 days)
Title
Number of In-hospital deaths
Description
Death during hospital stay
Time Frame
From hospital admission to hospital discharge (usually within the first 21 days)
Title
Number of severe vasospasms requiring endovascular treatment
Description
Number of severe vasospasms requiring endovascular treatment
Time Frame
From hospital admission to hospital discharge (usually within the first 21 days)
Title
Number of patients needing decompressive hemicraniectomy
Description
Operative intervention needed for high intracranial pressure
Time Frame
From hospital admission to hospital discharge (usually within the first 21 days)
Title
Difference in modified RankingScale
Description
Scale ranges from 0-5 (0 = no symptoms; 5= severe disability)
Time Frame
At day 90 and 180
Title
Difference in Glasgow Outcome Scale
Description
Scale ranges from 1-8 (1 is dead 7 good recovery)
Time Frame
At day 90 and 180
Title
Difference in mini Montreal Cognitive Assessment
Description
Max score depends on age and education (the higher the score the better the cognition)
Time Frame
At day 90 and 180
Title
Difference in Long-term mortality
Description
Death at 90 and 180 day
Time Frame
At day 90 and 180
Title
Length of stay
Description
Length of hospital stay
Time Frame
ICU stay and hospital stay (usually between 1-30days)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All adult patients suffering from non-traumatic subarachnoid haemorrhage.
Exclusion Criteria:
Patients with major intra-cranial trauma
Diagnosis of an AV-malformation as the source of subarachnoid hemorrhage on the primary CT/MRI or angiography
More than 24 hours after diagnosis of subarachnoid haemorrhage as diagnosed by cerebral imaging (CT scan or MRI)
Patients with clear limitation to therapy at hospital admission (eg ICU admission for evaluation of organ donation)
Declining of informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anna S Messmer, MD
Phone
+41316322111
Ext
0041
Email
anna.messmer@insel.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Research Nurses Department of Intensive Care
Phone
+41316322111
Ext
0041
Email
kim.researchnurses@insel.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anna S Messmer, MD
Organizational Affiliation
Department of Intensive Care, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna S Messmer, MD
Phone
0041316322111
Email
anna.messmer@insel.ch
Facility Name
Department of Intensive Care Medicine
City
Geneva
ZIP/Postal Code
1205
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hervé Quintard, Prof. Dr. med.
Phone
+41 223727460
Email
Herve.Quintard@hcuge.ch
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Information will be available upon request.
Learn more about this trial
Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage
We'll reach out to this number within 24 hrs